Otonomy - Top 15 Biotech VC Deals of 2010

Company: Otonomy
Based: San Diego
Amount: $49.07M

Investors: Novo Ventures, Avalon Ventures, RiverVest Venture Partners, Domain Associates, and TPG Biotech.

Scoop: Otonomy closed a $38.5 million Series B financing last August. Novo Ventures and RiverVest Venture Partners co-led the round with help from Domain Associates and TPG Biotech. Otonomy had earlier in the summer raised $10 million. 

Otonomy's lead product is OTO-104. This sustained-release steroid is being evaluated in a Phase Ib trial as a treatment for Meniere's disease, a condition that can affect hearing and balance. The developer also is working on OTO-203, a combination product for middle ear infections.

Otonomy - Top 15 Biotech VC Deals of 2010

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.